Effects of Daratumumab(dara), Cyclophosphamide (C), Thalidomide (T) and Dexamethasone (D) Combination on Lymphocyte Populations of Transplant Eligible Newly Diagnose Multiple Myeloma Patients

被引：0

作者：

Santos, Allan ^{[1
]}

Santos, Herbert ^{[2
]}

Leal, Joanna ^{[3
]}

Santos, Juliana ^{[2
,3
]}

Salvino, Marco ^{[4
]}

Lucas, Larissa ^{[3
]}

Santos, Mariane ^{[1
]}

Hungria, Vania T. M. ^{[5
]}

Torres, Alex ^{[6
]}

Crusoe, Edvan de Queiroz ^{[7
]}

机构：

[1] Univ Fed Bahia, Immunol & Cytometry Lab, Salvador, BA, Brazil

[2] Univ Fed Bahia, Salvador, BA, Brazil

[3] Oncol DOr BA Brazil, Salvador, BA, Brazil

[4] Univ Fed Bahia, Bone Marrow Transplantat unit, Salvador, BA, Brazil

[5] Clin Sao Germano Sao Paulo, Dept Hematol, Sao Paulo, Brazil

[6] Univ Fed Bahia, Inst Ciencias Saude, Salvador, BA, Brazil

[7] Rede Dor Oncol, Salvador, BA, Brazil

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-244

引用

页码：S178 / S179

页数：2

共 50 条

[41] Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study
Hulin, Cyrille
Offner, Fritz
Moreau, Philippe
Roussel, Murielle
Belhadj, Karim
Benboubker, Lotfi
Caillot, Denis
Facon, Thierry
Garderet, Laurent
Kuhnowski, Frederique
Stoppa, Anne-Marie
Kolb, Brigitte
Tiab, Mourad
Jie, Kon-Siong
Westerman, Matthijs
Lambert, Jerome
Pei, Lixia
Vanquickelberghe, Veronique
de Boer, Carla
Vermeulen, Jessica
Kampfenkel, Tobias
Sonneveld, Pieter
van de Donk, Niels W. C. J.
HAEMATOLOGICA, 2021, 106 (08) : 2257 - 2260
[42] Phase 3 randomized study of daratumumab (DARA) plus bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results.
Moreau, Philippe
Attal, Michel
Hulin, Cyrille
Bene, Marie-Christine
Broijl, Annemiek
Caillot, Denis
Delforge, Michel
Dejoie, Thomas
Facon, Thierry
Lambert, Jerome
Leleu, Xavier
Macro, Margaret
Perrot, Aurore
Zweegman, Sonja
Ahmadi, Tahamtan
Chiu, Christopher
Pei, Lixia
Vermeulen, Jessica
Avet-Loiseau, Herve
Sonneveld, Pieter
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[43] Pomalidomide, Cyclophosphamide and Dexamethasone (PCD) is an effective salvage regimen for multiple myeloma (MM) patients relapsed and/or refractory to Daratumumab (dara)
Brioli, A.
Ernst, T.
Hilgendorf, I.
Heidel, F.
Hunstig, F.
Stauch, T.
Hochhaus, A.
von Lilienfeld-Toal, M.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 278 - 278
[44] Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)
Yimer, Habte
Melear, Jason
Faber, Edward
Bensinger, William
Burke, John M.
Narang, Mohit
Stevens, Don
Gunawardena, Sriya W.
Lutska, Yana
Qi, Keqin
Ukropec, Jon
Qi, Ming
Lin, Thomas
Rifkin, Robert M.
BLOOD, 2018, 132
[45] Comparison of thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant eligible
R Soutar
M Steel
A Donaldson
C Walbaum
Annals of Hematology, 2020, 99 : 905 - 906
[46] Comparison of thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant eligible
Soutar, R.
Steel, M.
Donaldson, A.
Walbaum, C.
ANNALS OF HEMATOLOGY, 2020, 99 (04) : 905 - 906
[47] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca W.
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne A.
Holstein, Sara A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Lutska, Yana
Bobba, Padma
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter M.
BLOOD, 2020, 136
[48] Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update
Voorhees, Peter M.
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca W.
Costa, Luciano J.
Anderson, Larry D.
Nathwani, Nitya
Shah, Nina D.
Efebera, Yvonne A.
Costello, Caitlin L.
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Murphy, Sean
Lutska, Yana
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
de Boer, Carla
Hoehn, Daniela
Lin, Thomas S.
Richardson, Paul G.
BLOOD, 2019, 134
[49] Cyclophosphamide, thalidomide and dexamethasone (CTD) as initial therapy for newly diagnosed multiple myeloma patients.
Chavez, Jule Franve Vasquez
Mendoza, Rossana Esther Ruiz
Llerena, Karina Mayra Aliaga
Valencia, Fernando
Enriquez, Daniel
Palacios, Victor
Casanova, Luis
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[50] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca W.
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne A.
Holstein, Sara A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Lutska, Yana
Bobba, Padma
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter M.
BLOOD, 2021, 138

← 1 2 3 4 5 →